The U.S. AI in oncology market size accounted for USD 562 million in 2024 and is predicted to touch around USD 6,900 million by 2034, growing at a CAGR of 28.3% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 722 Million |
| Market Size by 2034 | USD 6,900 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 28.3% |
The U.S. AI in the oncology market is an emerging industry that deals with the use and application of Artificial Intelligence in the field of oncology. Oncology refers to the branch of medicine that primarily focuses on the treatment and diagnosis of cancer. Artificial intelligence helps improve the treatment and diagnosis procedures. AI techniques help to address and cater to different aspects of cancer, right from early diagnosis to a streamlined treatment, everything is enhanced using Artificial Intelligence. AI finds its applications in the detection of cancer, drug discovery, research and development, data analysis, etc.
Many different factors work together efficiently to drive the U.S. AI in the oncology market. However, three major factors primarily contribute more toward increasing the market’s growth. These include the increasing need for precision medicine, technical advancements, and the prevalence of data. All of these major drivers help in developing a more accurate and personalized treatment, tailored according to the patient’s needs. This emphasis on tailored cancer treatment to suit the patient leads to an increase in the demand for precision medicine. This helps develop a treatment based on the patient’s unique genetic and molecular profiles.
Another major driver that contributes incessantly to U.S. AI in the oncology market’s growth is the rapid refinement seen in today’s technology. With advanced technology and machine learning, AI has now gained insight and is developed enough to capture tiny and subtle patterns, often missed by humans. And the last of the three major drivers is the availability of data in bulk. The increase in high-quality data is important in training AI models. Be it clinical data or imaging data, it helps AI algorithms learn through experiences.
Except for the ones mentioned above, certain factors significantly contribute to the growth of the U.S. AI in the oncology market. These comprise radiotherapy optimization, where AI helps improve planning, image segmentation, and early cancer detection, AI-automated tasks also allow for reducing the time required to complete a task manually along with down costs.
Artificial intelligence has now become a great way to get things done easily and is easily available at one’s fingertips. It is also greatly contributing to driving the growth of the U.S. AI in the oncology market. With the integration of artificial intelligence and manufacturing processes, there is a significant increase in production rates. Artificial intelligence not only helps with the optimization of manufacturing processes but also replaces time-consuming tasks like analyzing complex data and predictive analysis. AI has proved to be very useful in analyzing large amounts of data, which has led to quicker development of treatment processes. Almost every step in this process is optimized using artificial intelligence. With the integration of artificial intelligence and the manufacturing process, the market ensures smooth and quick procedures tailored to suit the consumer’s preferences.
The U.S. AI in the oncology market is expected to expand and grow in a few years with the introduction of advanced technology and mechanization. Some new and upcoming drivers in the market will help the market grow as well as expand all over the globe. These include factors such as increasing demand for personalized treatments, a growing number of aging people, growth in the medical industry, and technical advancements that may improve manufacturing procedures and allow faster production.
Published by Rohan Patil
